<DOC>
	<DOC>NCT00199368</DOC>
	<brief_summary>This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.</brief_summary>
	<brief_title>An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018</brief_title>
	<detailed_description>Patients with Parkinson's disease with motor complications on levodopa therapy who completed the prior double-blind studies 6002-EU-007, 6002-US-013 or 6002-US-018 are eligible to enter into this 1-year, long-term open safety study with a starting istradefylline dose of 40mg per day.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Completion of study 6002EU007, 6002US013 or 6002US018 Nonpregnant and either not of childbearing potential or using specified contraception History of psychotic illness Variant/atypical Parkinson's disease Cancer within 5 years of enrollment ALT/AST levels &gt; 1.5 times ULN Seizure disorder Neuroleptic malignant syndrome</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Parkinson's disease</keyword>
	<keyword>levodopa</keyword>
	<keyword>end of dose wearing off</keyword>
	<keyword>OFF time</keyword>
</DOC>